Altria-backed Micreos is working on a clinical platform that will facilitate the targeted killing of unwanted bacteria, and has just secured $37.5m.
Micreos, a Netherlands-based endolysin technology developer backed by cigarette producer Altria, raised €32m ($37.5m) in funding from undisclosed investors yesterday.
Founded in 2005, Micreos is working on technology utilising endolysins – hydrolytic enzymes that can attack specific unwanted bacteria while leaving the remainder of the microbiome intact and thus present an advantage over antibiotics.
The technology was developed with university ETH Zurich, and Micreos will use the money to accelerate the development of its lead assets targeting atopic dermatitis, diabetic…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
